Amylyx Pharma Q3 net loss bigger than expected
AMLX•Amylyx reported a third-quarter net loss of $45.49 million, above the $43.70 million estimate, while loss per share of $0.38 matched expectations. The company reported positive Phase 3 LUCIDITY trial results for avexitide and expects to submit an NDA by the end of 2026.
1. Quarterly results
Amylyx reported a third-quarter net loss of $45.49 million, compared with analyst estimates of $43.70 million. Operating loss was $49.66 million, wider than the $46.22 million estimate, while loss per share of $0.38 matched expectations.
2. Avexitide plans
The company reported positive topline results from its Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia. Amylyx expects to submit an NDA for avexitide by the end of 2026 and is preparing for a potential 2027 launch if the drug is approved. It also targets an IND filing for AMX0318 in 2027.
3. Higher costs
Research and development expenses increased, driven by the LUCIDITY trial and avexitide programs. Selling, general and administrative expenses also rose due to hiring and pre-commercialization activities.
